These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 15705456

  • 1. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; ; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 3. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 4. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.
    Ann Intern Med; 2005 Feb 01; 142(3):157-64. PubMed ID: 15684203
    [Abstract] [Full Text] [Related]

  • 5. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA.
    Lancet; 2004 May 29; 363(9423):1751-6. PubMed ID: 15172772
    [Abstract] [Full Text] [Related]

  • 6. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 7. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 09; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 8. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 09; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 9. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM, Lévesque LE, Zhang B.
    Heart; 2007 Feb 09; 93(2):189-94. PubMed ID: 16849374
    [Abstract] [Full Text] [Related]

  • 10. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F, Harford WV, Kazi S, Little BB, Cryer B.
    J Cardiovasc Pharmacol Ther; 2008 Dec 09; 13(4):252-60. PubMed ID: 18787084
    [Abstract] [Full Text] [Related]

  • 11. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M, Richard H, Pilote L.
    BMJ; 2005 Jun 11; 330(7504):1370. PubMed ID: 15947399
    [Abstract] [Full Text] [Related]

  • 12. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
    Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR.
    Lancet; 2002 Oct 05; 360(9339):1071-3. PubMed ID: 12383990
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 05; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 14. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Nov 05; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 15. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 16. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 17. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
    Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.
    Arch Intern Med; 2003 Feb 24; 163(4):481-6. PubMed ID: 12588209
    [Abstract] [Full Text] [Related]

  • 18. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 24; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 19. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 24; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 20. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J, Coupland C, Logan R.
    BMJ; 2005 Dec 03; 331(7528):1310-6. PubMed ID: 16322018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.